Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed a delivery platform using hyaluronic acid-based dissolvable microneedles with nanoliposomes containing kopexil and kopyrrol, which showed improved hair regeneration for treating androgenetic alopecia in vivo at lower dosages compared to minoxidil.

This review discusses the potential of using sustained release systems to increase the effectiveness and reduce side effects of 17-alpha-estradiol in alopecia treatment and reports no clinical results.

This review discusses ethosomes as potential carriers for delivering drugs into deeper skin layers and provides no new clinical results, suggesting a need for further studies on their efficiency in dermal therapies.

This study found that transethosomal gel loaded with propranolol hydrochloride prolonged drug release and increased peak plasma concentration compared to an oral tablet, suggesting a promising alternative for delivery.

This study describes the development of microneedle array patches for finasteride that released the drug over 7 to 14 days in vitro, suggesting a potential alternative to oral treatments for long-term management of benign prostatic hyperplasia and androgenic alopecia.

This study found that Spironolactone-loaded ethosomal gels provided superior skin permeation and deposition compared to niosomal gels in rabbit skin, suggesting that ethosomal gels could be a promising formulation for further clinical studies on treating androgenic alopecia.

This study suggests that using nanostructured lipid carriers may improve the targeting of 17-α-estradiol in treating alopecia by improving skin penetration and stability.

In this study, lysocellin induced G1 phase arrest in human osteosarcoma cells, but diminished the cytotoxic efficacy of etoposide, while its derivative alopestatin may reduce etoposide-induced alopecia in a rat model.

This study found that tensed Silastic-Dacron strips completely prevented stretch-back and sometimes compressed the remaining bald area after alopecia-reducing procedures, whereas retention sutures provided only partial prevention.

This open-access journal publishes innovative research articles across various fields but reports no new clinical results in this summary.

This case report documented the management of a 46-year-old female with Marine-Lenhart syndrome, combining antithyroids with minimally invasive sclerotherapy to achieve euthyroidism and reduce thyroid nodule size by 58%.

The new system makes hair transplants faster and more precise.

This study suggests that sericin microneedles with antibacterial and directional traction functionalities may enhance infected wound healing by improving skin repair and inhibiting bacterial growth, indicating potential for clinical application.

In this case study, researchers found that treatment with sarolaner led to complete recovery from generalized demodicosis in six dogs within four weeks, resolving clinical signs without adverse reactions.

This study found that the newly developed microarray patches for intradermal delivery of finasteride showed high drug content and significantly improved skin deposition compared to existing methods.

This study developed a grooved microneedle platform enabling precise transdermal delivery of triamcinolone acetonide for alopecia areata, achieving accurate dosing by controlling groove position and drug concentration.

This presentation highlighted future directions in acne care, emphasizing the roles of topical and oral antibiotics, as well as skin microbiome studies. It also described how clascoterone targets androgen receptors in hair follicles and sebaceous glands to reduce sebum production.

In this study, hairline lowering using the Endotine Forehead-mini showed significant, sustained improvement in facial harmony with a reduction in the upper facial third ratio; however, 26% of patients experienced complications, including transient alopecia and the need for additional surgery.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

This study found that a topical transethosomal system may enhance the skin penetration and deposition of naftifine compared to a marketed cream, potentially overcoming the stratum corneum barrier.

This study found that cefazolin-loaded silica nanoparticles embedded in polycaprolactone nanofibers successfully inhibited Staphylococcus aureus growth while maintaining stem cell viability, suggesting their potential use in wound healing.

In this open-label study, participants reported that the LustrivaTM BH-002 two-step system improved various aspects of hair, skin, and nail health and appearance after three months of use.

This study found that using Labrasol® in phospholipid vesicle formulations improved minoxidil's skin delivery and local accumulation, showing potential for treating hair growth disorders.

This study found that administering steroids alongside cochlear implantation using Skarżyński's six-step method helped preserve residual hearing in patients, with a higher hearing preservation rate observed in those receiving steroids compared to those without.

This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.

In this study, researchers developed a biodegradable microneedle made of hyaluronic acid, intended to enhance drug delivery through the skin's stratum corneum and potentially promote hair growth by overcoming the skin's barrier function in alopecia treatment.

This study suggests that leukocyte-platelet-rich fibrin membranes may aid postoperative healing in endoscopic skull base surgery, with some patients showing reduced crusting and low rates of cerebrospinal fluid leaks.

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

This abstract provides contact information for François Kuonen at the Lausanne University Hospital Center and reports no new research findings.